A Phase 1 Study of TYRA-300 in People with Advanced Bladder Cancer


Full Title

A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)


The purpose of this study is to find the highest dose of the investigational drug TYRA-300 that can be given safely in people with advanced urothelial carcinoma (a type of bladder cancer). TYRA-300 blocks the activity of FGFR, a protein that helps some cancer cells grow. Blocking this protein could slow or stop the growth of cancer. TYRA-300 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced urothelial cancer with an FGFR3 gene mutation.
  • At least 2 weeks must pass between the completion of previous treatment and receipt of TYRA-300.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Gopakumar Iyer at 646-888-4737.




Phase I/II (phases 1 and 2 combined)



ClinicalTrials.gov ID